Skip to main content

Nuopu Regenerative Medicine

ApplicationSuzhou, ChinaFounded 2016· One of 702 Application companies tracked by AMPulse

Develops and manufactures patient-specific, biodegradable bone regeneration scaffolds for oral and maxillofacial surgery using its proprietary OPUS bio-3D printing extrusion platform.

CEO / Founder
Xi Yang
Team Size
11-50
Stage
Established
Total Funding
$5M
Latest Round
Series B
Key Investors
Qiming Venture Partners (启明创投); Daotong Investment (道彤投资); Yuansheng Venture Capital (元生创投); Wuzhong Gaoke Venture Capital (吴中高科创投); Yuanhe Holdings (元禾控股); Sequoia China / HongShan (红杉中国); Taihao Venture Capital (太浩创投)

Technology & Products

Key Products

OPUS bio-3D printing platform; NMPA-certified Class III medical device bone filler for alveolar defect repair

Technical position · AMPulse analysis

Proprietary extrusion-based bioprinting process for creating single-piece, biodegradable, porous scaffolds with controlled architecture, protected by patents (e.g., CN105802851A, CN119283364A). The regulatory approval creates a significant barrier to entry in the Chinese medical AM market.

Patent position

Nuopu filed 9 patent families in 2022-2024 versus 7 in 2019-2021, up 29% while tracked AM filings in the same patent offices rose just 8%, and it leads named peer Dimension Bio's 7 total families. Its focus mix shifted too, with Applications share falling from 86% to 63%. AMPulse analysis

Filing momentum
9 families filed 2022–2024, 7 in 2019–2021 (+29%); all tracked AM filings in the same offices +8%
Focus, 2019–2021 → 2022–2024
Applications 86% → 63%
Filed in
CN 100%
Named competitors, AM patent families
Dimension Bio 7

17 AM patent families in total. Recent years are still being published, so read a filing change against the same-office figure.

Differentiation

Value Proposition

Eliminates secondary trauma from autologous bone harvesting and immunological risks of allografts by providing a personalized, structurally supportive, and osteoconductive scaffold that improves anatomical fit and clinical outcomes in complex bone defects.

How They Differentiate

Focuses on regulatory-approved, patient-specific bone scaffolds via extrusion bioprinting, unlike generic bone graft substitutes or non-resorbable implants.

Market & Competition

Target Customers

Hospitals, dental clinics, and surgeons specializing in oral and maxillofacial reconstruction

Industry Verticals

Medical Devices; Regenerative Medicine; Dentistry

Competitors

Johnson & Johnson (traditional implants; named by CEO); Medtronic Infuse (BMP-2 grafts; compared in company materials); Dimension Inx / CMFlex (FDA 3D-printed synthetic bone graft; cited as US analogue)

Growth & Milestones

Growth Metrics

Received China's first Class III medical device registration for an additively manufactured oral bone filler material in April 2026.

Major Milestones

Obtained NMPA Class III medical device registration certificate for its AM bone filler (first in China for this technology)

https://www.novaprint.cn

Recent coverage of Nuopu Regenerative Medicine

AM patents

AM-relevant patents linked to this company.

Patents
17
Granted
5
Families
17

Leading domains: process (17), application (11), equipment (5)

Filings by year: 2024: 2 · 2023: 5 · 2022: 2 · 2021: 1 · 2020: 5 · 2019: 1

  1. A composite scaffold of 3D printing degradable polymer scaffold and photocrosslinked hydrogel111166933 · CN
  2. Multi-degree-of-freedom biological 3D printing system for in-vitro reconstruction of curved tissue116252477 · CN
  3. Degradable composite material for biological 3D printing and preparation method thereof109320950 · CN
  4. Bidirectional uniform temperature control platform and biological 3D printer119283364 · CN
  5. Composite skull meninx repair stent as well as additive manufacturing method and application thereof115252907 · CN